Secondary outcome measures were end of treatment virological response, biochemical response, histological response, and adverse events.
次级结果的测量方法是治疗结束时的病毒学应答、生化应答以及组织学应答和不良反应。
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naive patients with a partial virological response...
恩替卡韦治疗慢性乙型肝炎：大多数的部分病毒学应答初治患者无需剂量调整。
Standard of care resulted in sustained virological response (SVR) rates of 38% and 81% in treatment-experienced and treatment-naïve patients, respectively.
标准治疗导致出现持续病毒学反应（SVR）的复治和初治患者比例分别为38%和81%。
These patients have a high likelihood of SVR (Sustained Virological Response) - probably 70-80% - and in the absence of any contraindications of therapy they are very good candidates.
这类患者出现持续病毒学应答(SVR)的机率很高——大概是70%到80%，且无治疗的禁忌症，是非常好的治疗对象。
This will comprise of direct antiviral drugs such as protease inhibitors along with peg-Interferon and ribavirin. This can provide a sustained virological response in over 70% of patients.
应用三联疗法的患者中，超过70%的患者能够达到持续病毒学应答，同时对难治性基因型患者也能获得很好的疗效。
This will comprise of direct antiviral drugs such as protease inhibitors along with peg-Interferon and ribavirin. This can provide a sustained virological response in over 70% of patients.
应用三联疗法的患者中，超过70%的患者能够达到持续病毒学应答，同时对难治性基因型患者也能获得很好的疗效。
应用推荐